Published in BMC Cancer on May 28, 2012
Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One (2013) 1.33
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 0.92
HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics. Int J Mol Sci (2013) 0.92
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis (2013) 0.87
Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol Cancer Ther (2014) 0.81
Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis (2014) 0.80
Ggnbp2 Is Essential for Pregnancy Success via Regulation of Mouse Trophoblast Stem Cell Proliferation and Differentiation. Biol Reprod (2016) 0.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol (1979) 6.96
Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 6.91
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci U S A (1989) 2.61
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res (2006) 2.48
Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res (1997) 2.30
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med (2009) 2.10
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 2.02
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol (1995) 1.94
Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther (2010) 1.94
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest (2002) 1.93
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol (1995) 1.83
Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res (2010) 1.74
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol (1996) 1.58
Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res (2005) 1.39
Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res (1997) 1.36
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med (2010) 1.19
Molecular cancer therapy: can our expectation be MET? Eur J Cancer (2008) 1.19
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol (2001) 1.17
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A (2008) 1.13
E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res (2010) 1.10
The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene (2009) 1.08
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther (2010) 1.08
Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate (1999) 1.07
Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol (1998) 0.99
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res (2008) 0.96
Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol (2004) 0.96
Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate (2009) 0.94
Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ (1996) 0.94
Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Oncol Rep (2003) 0.88
The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer (2003) 0.86
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res (2008) 0.85
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis (2012) 0.79
Effects of serum on hepatocyte growth factor secretion and activation by periodontal ligament and gingival fibroblasts. J Periodontol (2002) 0.78
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res (2006) 2.00
Leukemia regression by vascular disruption and antiangiogenic therapy. Blood (2010) 1.60
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res (2003) 1.35
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol (2010) 1.34
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res (2006) 1.22
Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs (2006) 1.18
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood (2009) 1.15
E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res (2010) 1.10
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther (2010) 1.08
Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys (2011) 1.04
Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst (2014) 1.02
Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys (2007) 1.00
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis (2011) 0.93
Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res (2006) 0.91
Cell-based selection provides novel molecular probes for cancer stem cells. Int J Cancer (2013) 0.91
Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther (2002) 0.89
Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol (2002) 0.88
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. Eur J Cancer (2006) 0.88
Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol (2002) 0.88
Postoperative radiation therapy for squamous cell carcinoma of the head and neck. Am J Otolaryngol (2003) 0.88
Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol (2003) 0.88
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys (2006) 0.88
Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res (2005) 0.87
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis (2013) 0.87
Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. Radiat Res (2003) 0.86
Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs (2010) 0.85
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. J Clin Invest (2016) 0.84
Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvasc Res (2010) 0.84
Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood (2012) 0.84
In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. Oncol Rep (2010) 0.84
Monitoring the treatment efficacy of the vascular disrupting agent CA4P. Eur J Cancer (2007) 0.83
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo (2005) 0.83
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol (1985) (2013) 0.82
Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines. Am J Vet Res (2008) 0.82
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Biol (2011) 0.80
Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proc Natl Acad Sci U S A (2011) 0.79
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Res (2010) 0.79
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis (2012) 0.79
Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. Microvasc Res (2012) 0.78
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia (2013) 0.78
Cell proliferation index determination by immunohistochemical detection of hCDC47 protein. Appl Immunohistochem Mol Morphol (2010) 0.78
Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. Am J Vet Res (2009) 0.77
Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial. Cancer (2005) 0.77
Vascular development in mouse lung metastases. Am J Cancer Res (2012) 0.77
Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach. Anticancer Res (2004) 0.77
Impact of VEGF expression on the physiological characteristics of clonal cell lines. In Vivo (2007) 0.77
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. Am J Vet Res (2013) 0.76
Another road leads to HIF-1 activation: implications for prostate cancer progression. Asian J Androl (2011) 0.75
Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol (2004) 0.75
Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. Anticancer Res (2006) 0.75
The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USA. Expert Opin Pharmacother (2002) 0.75
Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model. Anticancer Drugs (2014) 0.75